Reduce the mortality of specific hospitalized patients by 20%, the phase 3 clinical results of the new crown neutralizing antibody combination are positive

On June 16, 2021, Regeneron announced that its research neutralizing antibody therapy REGEN-COV (casirivimab and imdevimab) has obtained positive preliminary results in the Phase 3 clinical trial RECOVERY

REGEN-COV is a cocktail therapy consisting of two monoclonal antibodies, which can be administered by intravenous infusion or subcutaneous injection

A total of 9785 COVID-19 hospitalized patients were enrolled in this phase 3 clinical trial, with an average age of 62 years.

The results of the test showed that, similar to previous studies, the mortality rate of seronegative patients on day 28 was twice that of serologically positive patients (30% vs.

In addition, among seronegative patients, the median hospital stay in the experimental group was 4 days shorter (13 days vs.

Note: The original text has been deleted

Reference materials:

[1] REGEN-COV™ (CASIRIVIMAB AND IMDEVIMAB) PHASE 3 RECOVERY TRIAL MEETS PRIMARY OUTCOME, IMPROVING SURVIVAL IN HOSPITALIZED COVID-19 PATIENTS LACKING AN IMMUNE RESPONSE TO SARS-COV-2.